利伐沙班拜瑞妥治疗什么病？

Xarelto is a new type of oral anticoagulant that has many obvious advantages over other traditional drugs. Rivaroxaban tablets were jointly developed by Bayer and Johnson & Johnson. On September 15 and October 1, 2008, Xarelto Rivaroxaban tablets were approved for marketing in Canada and the European Union respectively. Today let’s take a closer look at what diseases Rivaroxaban Xarelto treats?

Indications for Rivaroxaban Xarelto Tablets include:

1. For use in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

Rivaroxaban Xarelto is contraindicated in the following groups: 1. Patients who are allergic to Rivaroxaban Xarelto or any excipients in the tablets. 2. Patients with clinically obvious active bleeding. 3. Lesions or conditions with a significant risk of major bleeding, such as current or recent gastrointestinal ulcers, malignant tumors with a high risk of bleeding, recent brain or spinal injury, recent brain, spine or eye surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or major intravertebral or intracerebral vascular malformations. 4. Except for switching from other treatments to rivaroxaban or from rivaroxaban Xarelto to other treatments, or giving the unfractionated heparin (UFH) dose required to maintain a central venous or arterial catheter, any concomitant treatment with other anticoagulants is prohibited, such as UFH, low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, apixaban, dabigatran, etc.).

5. Patients with liver disease associated with coagulation abnormalities and clinically relevant bleeding risks, including patients with cirrhosis reaching Child Pugh classes B and C. 6. Pregnant and lactating women are contraindicated in taking rivaroxaban and Xarelto.

The above is the indications of Xarelto, I hope it can help you!

Recommended related hot articles: /newsDetail/83307.html